FIG. 4.
In vivo efficacy of vancomycin products available in Colombia during 2008 against S. aureus GRP-0057 at low (A) and very high (B) inocula (4.07 and 8.34 log10 CFU per thigh when subcutaneous treatment q1h started, respectively). After VAN-Lilly was discontinued, VAN-Baxter replaced it as the innovator product; both panels show its dose-effect relationship compared with those of the newest version of VAN-Abbott (commercialized under the brand name Hospira) and VAN-Proclin. At a low inoculum, VAN-Hospira was indistinguishable from VAN-Baxter while VAN-Proclin was again ineffective; the very high inoculum had a marked impact on vancomycin pharmacodynamics, but VAN-Proclin remained inferior despite losing its Eagle effect.